JW (Cayman) Therapeutics Co. Ltd (HKG:2126)
Hong Kong · Delayed Price · Currency is HKD 2.260
-0.050 (-2.16%)
Feb 13, 2026, 4:08 PM HKT
HKG:2126 Revenue
JW (Cayman) Therapeutics Co. had revenue of 106.35M CNY in the half year ending June 30, 2025, with 21.21% growth. This brings the company's revenue in the last twelve months to 177.75M, up 2.79% year-over-year. In the year 2024, JW (Cayman) Therapeutics Co. had annual revenue of 158.22M, down -8.99%.
Revenue (ttm)
177.75M CNY
Revenue Growth
+2.79%
P/S Ratio
4.71
Revenue / Employee
608.73K CNY
Employees
292
Market Cap
916.74M HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 158.22M | -15.64M | -8.99% |
| Dec 31, 2023 | 173.86M | 28.15M | 19.32% |
| Dec 31, 2022 | 145.70M | 114.91M | 373.10% |
| Dec 31, 2021 | 30.80M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Uni-Bio Science Group | 589.59M |
| 3D Medicines | 491.34M |
| Wuhan YZY Biopharma | 163.65M |
| CANbridge Pharmaceuticals | 68.55M |
| Beijing Biostar Pharmaceuticals | 58.66M |
| Brii Biosciences | 31.53M |
| Kintor Pharmaceutical | 12.04M |
| Transcenta Holding | 10.31M |